Fierce Biotech July 29, 2024
Earlier this month, Flagship Pioneering hinted that another Big Pharma may soon join its growing fleet of collaborators. Now, GSK has sailed into view.
The British drugmaker and the venture creation firm will put a combined $150 million upfront towards a respiratory and immunology-focused research project, which will involve Flagship’s portfolio of over 40 biopharma companies. The goal is to identity up to 10 novel medicines and vaccines, for which GSK will have an exclusive option to take forward for further clinical development.
For each program that GSK picks up, Flagship and its companies will be eligible to receive up to $720 million in upfront, development and commercial milestones from GSK, as well as preclinical funding and tiered royalties on...
Today's Sponsors
Today's Sponsor